List view / Grid view
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
